Skip Navigation LinksHome > December 2013 - Volume 13 - Issue 6 > Subcutaneous immunoglobulin replacement therapy: the Europea...
Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0000000000000013
PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by Ramsay L. Fuleihan and Bruce D. Mazer

Subcutaneous immunoglobulin replacement therapy: the European experience

Chapel, Helena; Gardulf, Annb

Collapse Box

Abstract

Purpose of review

Rapid subcutaneous immunoglobulin (SCIg) infusions have been used as an important method of delivering replacement immunoglobulin (Ig) to patients with primary immune deficiencies (PIDs) in Europe over the last 25 years. This review provides a comprehensive interpretation of the literature relating to the administration of SCIg and the services that have been developed alongside.

Recent findings

Using rates of at least 20 ml/h per infusion site and simultaneous sites, the infusion time once per week is short (1–2 h in adults) and using small portable pumps, the child or adult is free for other activities during the therapy. The rapid SCIg infusions have been documented as well tolerated, efficacious and acceptable to infants and their parents, children, adults and elderly patients, and more recently to patients with autoimmunity requiring immunomodulatory Ig doses.

Summary

As part of PID diagnostic and management services, educational programmes for self-infusion of both intravenous Ig and SCIg at home have been developed throughout Europe, resulting in increased patient compliance and patient empowerment as well as cost-savings for healthcare providers.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.